Company launches clinical trial of GLP-1 implants for weight loss in cats

Okava Pharmaceuticals, a San Francisco-based biopharmaceutical firm, is preparing to initiate a groundbreaking clinical study aimed at reducing weight in household cats. The study, named MEOW-1, will test OKV-119, a small implant that delivers GLP-1 continuously for up to six months.

According to Okava, this is the first-ever trial to explore such an approach for pet weight loss. The trial will involve up to 50 cats, with initial results assessed after three months, though monitoring will continue for the full six months, stated Michael Klotsman, CEO of Okava Pharmaceuticals.

The company plans to submit the product for FDA approval between 2027 and 2028. The expected out-of-pocket cost for pet owners is around $100 per month. Okava emphasizes that weight management can significantly improve a cats health, reducing the risk of diabetes, alleviating joint pain, and ultimately extending lifespan.

Obesity is a major concern for cats, with over half of domestic felines classified as overweight or obese. The study will use exenatide as the GLP-1 agent, differing from human weight loss drugs like semaglutide (Ozempic) or tirzepatide (Mounjaro).

Okava highlights multiple potential benefits of using GLP-1 therapy in pets over conventional diet and exercise, including improved glucose metabolism, reduced osteoarthritis-related pain, enhanced cardiovascular function, and better insulin sensitivity. Early research indicates that the implant and GLP-1 treatment are safe and effective for cats.

Following the cat trial, Okava intends to explore similar treatments for dogs. The company notes that the medication acts in pets much like it does in humans, leading to behavioral changes such as reduced food-seeking behaviors and improved portion control. Owners may also notice increased activity levels as pets lose weight and their metabolic health improves.

GLP-1 drugs help by boosting insulin production and lowering blood sugar levels. They also slow gastric emptying and suppress appetite, promoting weight loss. Variants of GLP-1 medications have become increasingly popular as injectable treatments for obesity in humans.

Author: Sophia Brooks